Farnesoid X receptor promotes non-small cell lung cancer metastasis by activating Jak2/STAT3 signaling via transactivation of IL-6ST and IL-6 genes

Xiuye Jin,Bin Shang,Junren Wang,Jian Sun,Jing Li,Bin Liang,Xingguang Wang,Lili Su,Wenjie You,Shujuan Jiang

DOI: https://doi.org/10.1038/s41419-024-06495-y

2024-02-17

Cell Death and Disease

Abstract:Metastasis accounts for the majority of cases of cancer recurrence and death in patients with advanced non-small cell lung cancer (NSCLC). Farnesoid X Receptor (FXR) is a bile acid nuclear receptor that was recently found to be upregulated in NSCLC tissues. However, whether and how FXR regulates NSCLC metastasis remains unclear. In the present study, it was found that FXR promoted the migration, invasion, and angiogenic ability of NSCLC cells in vitro, and increased NSCLC metastasis in a mouse model in vivo. Mechanistic investigation demonstrated that FXR specifically bound to the promoters of IL-6ST and IL-6 genes to upregulate their transcription, thereby leading to activation of the Jak2/STAT3 signaling pathway, which facilitated tumor migration, invasion, and angiogenesis in NSCLC. Notably, Z-guggulsterone, a natural FXR inhibitor, significantly reduced FXR high NSCLC metastasis, and decreased the expression of FXR, IL-6, IL-6ST, and p-STAT3 in the mouse model. Clinical analysis verified that FXR was positively correlated with IL-6, IL-6ST and p-STAT3 expression in NSCLC patients, and was indicative of a poor prognosis. Collectively, these results highlight a novel FXR-induced IL-6/IL-6ST/Jak2/STAT3 axis in NSCLC metastasis, and a promising therapeutic means for treating FXR high metastatic NSCLC.

cell biology

What problem does this paper attempt to address?

This paper aims to explore the role and mechanism of Farnesoid X receptor (FXR) in the metastasis of non - small - cell lung cancer (NSCLC). Specifically, the researchers found that FXR promotes the migration, invasion and angiogenesis ability of NSCLC by activating the Jak2/STAT3 signaling pathway, thereby increasing the metastasis of NSCLC. In addition, the study also found that FXR specifically binds to the promoter regions of IL - 6ST and IL - 6 genes, up - regulates the transcription of these genes, and thus activates the downstream Jak2/STAT3 signaling pathway. Clinical analysis further confirmed the positive correlation between FXR and IL - 6, IL - 6ST and p - STAT3 in NSCLC patients, and suggested that high FXR expression is associated with poor prognosis. Finally, the study verified the anti - metastatic activity of an FXR inhibitor Z - guggulsterone against NSCLC with high FXR expression in vivo. In short, the problems that this paper attempts to solve are: - Is FXR involved in the metastasis process of NSCLC? - If so, what is the specific mechanism? - Can the inhibition of FXR be used as a new strategy for the treatment of NSCLC metastasis?

Farnesoid X receptor promotes non-small cell lung cancer metastasis by activating Jak2/STAT3 signaling via transactivation of IL-6ST and IL-6 genes

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

FXR Acts As a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.

Transcription Factor FXR Activates DHRS9 to Inhibit the Cell Oxidative Phosphorylation and Suppress Colon Cancer Progression

IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung

<i>Fusobacterium nucleatum</i> promotes colorectal cancer metastasis by modulating <i>KRT7-AS</i>/KRT7

FYN Promotes Gastric Cancer Metastasis by Activating STAT3-mediated Epithelial-Mesenchymal Transition

Hepatocarcinogenesis in FXR−/− Mice Mimics Human HCC Progression That Operates Through HNF1α Regulation of FXR Expression

Farnesoid X Receptor Overexpression Decreases the Migration, Invasion and Angiogenesis of Human Bladder Cancers via AMPK Activation and Cholesterol Biosynthesis Inhibition

Fas Signaling in Adipocytes Promotes Low-Grade Inflammation and Lung Metastasis of Colorectal Cancer Through Interaction with Bmx.

Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene

FSTL1 promotes growth and metastasis in gastric cancer by activating AKT related pathway and predicts poor survival

XCR1 Promotes Cell Growth and Migration and is Correlated with Bone Metastasis in Non-Small Cell Lung Cancer.

AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.

A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways

Stromal Cell-Derived Factor 1 Secreted by Cancer-Associated Fibroblasts Promotes lncRNA Xist through CXCR4 and Facilitates Invasion and Metastasis of Non-Small Cell Lung Cancer.

Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer

Farnesoid X receptor functions in cervical cancer via the p14ARF-mouse double minute 2-p53 pathway

XBP1- IGFBP3 Signaling Pathway Promotes NSCLC Invasion and Metastasis

Long Noncoding RNA ENST00000508435 Promotes Migration of Breast Cancer Via FXR 1.

WNT2-Mediated FZD2 Stabilization Regulates Esophageal Cancer Metastasis via STAT3 Signaling